Nasdaq
$5.44▲ 1.03%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $330.7MShares out 60.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 5d agoRegular26.10.20 03:29SCHEDULE 13GOwnership#●●●#●●●
Kyverna Therapeutics, Inc.
Investor Orin Hirschman has filed a Schedule 13G, reporting a beneficial ownership of more than 5% of Kyverna Therapeutics, Inc. This filing officially discloses the investor's significant stake in the company.…more
$5.44+1.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.24Pre-market26.09.24 19:008-KKey event
Kyverna Therapeutics, Inc.
Kyverna Therapeutics announced positive one-year data from its KYSA-8 registrational trial in Stiff Person Syndrome (SPS) and longer-term follow-up data from its KYSA-6 trial in generalized myasthenia gravis (gMG). The company remains on track to complete its rolling BLA submission for miv-cel in SPS by Q4 2026, with Phase 3 enrollment for gMG expected to finish in mid-2027.…more
$5.44+1.03%vs prev closeView filingShare - 8.11After-hours26.08.12 05:0710-QEarnings
Kyverna Therapeutics, Inc.
카이버나 테라퓨틱스는 2026년 7월 8일 대출 및 담보 계약을 수정하여 2,000만 달러 규모의 Term C 대출 시설을 추가하고 재무 약정을 변경했습니다. 또한 2026년 5월 4일부로 나디아 닥을 최고상업책임자(CCO)로 임명하며 연봉 52만 달러 및 30만 주의 스톡옵션 부여를 포함한 고용 계약을 체결했습니다.…more
$5.44+1.03%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoRegular26.10.23 23:30#●●●#●●●
Kyverna Therapeutics Reports Positive Phase 1 Clinical Data for Miv-cel in Progressive MS…more
Kyverna Therapeutics announced promising safety and efficacy results from its Phase 1 trial of miv-cel in patients with progressive multiple sclerosis. These preliminary findings require confirmation through larger controlled clinical trials.…more
$5.44+1.03%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 4d agoPre-market26.10.21 20:15
●●●●●●●● ●●●●● ●●●●●●
Kyverna Therapeutics announced that its CAR-T therapy, miv-cel, demonstrated sustained clinical benefit and a favorable safety profile in a one-year follow-up of its Phase 2 trial for stiff person syndrome. These results strengthen the company's regulatory filing package for potential FDA approval.…more
$5.44+1.03%vs prev close - 10.7Pre-market26.10.07 21:00
●●●●●●●● ●●●●● ●●●●●●
Kyverna Therapeutics announced that two of its abstracts have been selected for presentation at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto. The company will share its latest research on therapies for neurologic autoimmune diseases.…more
$5.44+1.03%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report